Clinical Trials · NCT05232708

A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide

CompletedPhase 1Semaglutide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
18
Start date
Jan 2022
Locations
1 site, United Kingdom
Primary endpoint
AUC0-last,sema 0.5mg: Area under the semaglutide concentration-time curve from time 0 until last quantifiable measurement after single dose of s.c. semaglutide 0.5 mg
View Semaglutide compound reference